Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis-Reference-Cited by-同舟云学术

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Published:2015-06 Issue: Volume:3 Page:21-27
ISSN:2214-4269
Container-title:Molecular Genetics and Metabolism Reports
language:en
Short-container-title:Molecular Genetics and Metabolism Reports

Author:

Beck Michael,Hughes Derralynn,Kampmann Christoph,Larroque Sylvain,Mehta Atul,Pintos-Morell Guillem,Ramaswami Uma,West Michael,Wijatyk Anna,Giugliani Roberto

Funder

Shire

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology

Reference30 articles.

1. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase;Garman;J. Mol. Biol.,2004

2. Natural course of Fabry disease: changing pattern of causes of death in FOS — Fabry Outcome Survey;Mehta;J. Med. Genet.,2009

3. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females;MacDermot;J. Med. Genet.,2001

4. Natural history of Fabry disease in affected males and obligate carrier females;MacDermot;J. Inherit. Metab. Dis.,2001

5. Agalsidase alfa and kidney dysfunction in Fabry disease;West;J. Am. Soc. Nephrol.,2009

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan;Molecular Genetics and Metabolism Reports;2024-09

2. Contemporary Multimodality Imaging for Diagnosis and Management of Fabry Cardiomyopathy;Journal of Clinical Medicine;2024-08-14

3. Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry;Journal of Inherited Metabolic Disease;2024-07-19

4. The Diagnostic and Therapeutic Implications of Phenocopies and Mimics of Hypertrophic Cardiomyopathy;Canadian Journal of Cardiology;2024-05

5. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data;Drug Design, Development and Therapy;2024-04